Among repurposed drugs, sulfasalazine inhibits TOPK, reduces p-AKT, and suppresses tumor proliferation and metastasis through the PI3K/AKT pathway, with significant in vivo antitumor effects at concentrations up to 150 μM 157. This evidence concerns the gene AKT1 and neoplasm.